Neurelis is a unique company focused on therapies for disorders involving the central nervous system. Our company is built on a foundation of passion and progress. This passion fuels our drive to succesfully deliver innovative therapies that have the potential to change the lives of patients, caregivers, and healthcare providers.
Neurelis is a neuroscience-based specialty pharmaceutical company dedicated to enhancing therapeutic benefit and addressing unmet needs in patient care.
Our pipeline currently includes NRL-1, an investigational product candidate being developed as an on-hand rescue treatment to control intermittent bouts of increased seizure activity (seizure emergencies). We also have two product candidates currently in the formulation stage of development. NRL-2 is being developed as a rescue treatment for acute anxiety episodes or panic attacks, and NRL-3 is being developed as a non-invasive acute therapy to stop siezures that have progressed to status epilepticus.